We have developed XOFLX® lentiviral packaging and producer cell lines to reduce or eliminate plasmid transfection during lentiviral vector (LVV) manufacturing, thus saving plasmid manufacturing cost, simplifying supply chain, and improving process robustness of LVV manufacturing. Previous LVV productions for several therapeutic cargo genes showed 1-9-fold higher titres from XOFLX® cell lines compared to the industry standard four-plasmid transfection method.
By increasing the cell seeding density from 2E6 cells/mL (standard production) to 5E6 cells/mL(intensified production), the LVV titre from the LV-EGFP Producer cell line was increased by 4-fold at 48 hours post induction, with approximately 100% increase in per-cell productivity.
We also mimicked the perfusion process by refreshing media for LV-producing cells in shake flasks and managed to extend the harvest window to up to 11 days post induction, showing the potential of developing a proper perfusion process for XOFLX® producer cell line.
